Patent Assignment
Reel/Frame 043753/0436
Merger
Recorded: 2017-10-02
Pages: 4
Assignor
TRUBION PHARMACEUTICALS, INC.
Executed: 2010-10-28
Assignee
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
2401 FOURTH AVENUE, SUITE 1050, SEATTLE, WASHINGTON, 98121
Covered Property
(1)
CD86 Antagonist Multi-Target Binding Proteins
Application:
15/281,441 →
Publication:
US 2017/0015747
Related Assignments
(4)
Other recorded transfers of the patent in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 2, 2017
From: THOMPSON, PETER A.; BAUM, PETER R.; TAN, PHILIP; BLANKENSHIP, JOHN W.
To: TRUBION PHARMACEUTICALS, INC.
Reel/Frame 043753/0398 →
Change of Name
Oct 2, 2017
From: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
To: APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 044097/0091 →
Security Interest
Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →
Release of Security Interest
Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →